Scarica l'app Stockscreener
36.34
0.03%
0.01
Pacira Biosciences Inc Borsa (PCRX) Ultime notizie
Seven investors report stakes below 5% in Pacira BioSciences (PCRX). - Stock Titan
Form 4 Pacira Pharmaceuticals Inc For: 12 October By Investing.com - Investing.com South Africa
Pacira BioSciences SVP Riker sells $217,920 stock - Investing.com
Pacira BioSciences SVP Riker sells $217,920 stock By Investing.com - Investing.com Canada
Pacira BioSciences SVP Lauren Riker sells $217,920 in stock - Investing.com
Form 4 Pacira Pharmaceuticals Inc For: 10 October By Investing.com - Investing.com South Africa
Pacira BioSciences SVP Lauren Riker sells $217,920 in stock - Investing.com
Form 4 Pacira Pharmaceuticals Inc For: 9 October By Investing.com - Investing.com South Africa
Pacira BioSciences senior vice president Lauren Riker sells $217,920 in stock By Investing.com - Investing.com South Africa
Form 4 Pacira Pharmaceuticals Inc For: 9 October By Investing.com - Investing.com Nigeria
Pacira BioSciences senior vice president Lauren Riker sells $217,920 in stock - Investing.com
After exercising options, Lauren Riker sells 6,000 Pacira BioSciences (PCRX) shares. - Stock Titan
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio - Zacks Investment Research
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio - TradingView
An offer for all Pacira BioSciences (PCRX) shares is planned but has not yet begun. - Stock Titan
No financing condition applies to the planned Viatris takeover of Pacira BioSciences (PCRX). - Stock Titan
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Pacira BioSciences (Nasdaq: PCRX) Makes 52 Week High on Acquisition News - Investorideas.com
Viatris Inc. entered into a definitive agreement to acquire Pacira BioSciences, Inc. for $1.6 billion. - marketscreener.com
Viatris to Acquire Pacira BioSciences for $36.50 Per Share in $1.65 Billion Cash Deal - Minichart
Why Pacira BioSciences Skyrocketed Today - The Motley Fool
Viatris Acquires Pacira BioSciences for $1.65 Billion - Pharmaceutical Executive
A 6,000-share sale is proposed by Lauren B. Riker of Pacira BioSciences (PCRX). - Stock Titan
With unanimous board backing, Pacira (PCRX) agrees to an all-cash Viatris takeover. - Stock Titan
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies - Viatris Newsroom
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies - PR Newswire
PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal - Zacks Investment Research
Pacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialize EXPAREL® in the European Union and United Kingdom - Orthopedics This Week
A postsurgery pain medicine is planned to launch in four countries; first sales are expected in 2027. - Stock Titan
Discipline and Rules-Based Execution in PCRX Response - Stock Traders Daily
Pacira Biosciences (NASDAQ:PCRX): An Undervalued Value Stock Backed by Cash Flow and Balance Sheet Strength - ChartMill
PACIRA BIOSCIENCES, INC. : LEERINK PARTNERS INITIATES COVERAGE WITH MARKET PERFORM RATING; PRICE TARGET $28 - webull.com
PCRX Initiated Coverage by Leerink Partners -- Rating Market Per - GuruFocus
Five new employees receive Pacira stock awards, vesting over four years - Stock Titan
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Pacira (PCRX) Up 6.9% Since Last Earnings Report: Can It Continue? - Yahoo Finance
(PCRX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Pacira BioSciences stock update with limited verified data - ad-hoc-news.de
Truist Financial Initiates Pacira BioSciences(PCRX.US) With Buy Rating - Moomoo
Pacira BioSciences Inc (PCRX) Stock Up 3.5% and Still Undervalued -- GF Score: 81/100 - GuruFocus
Foster & Motley Inc. Buys New Holdings in Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira (PCRX) Q2 2026 Results: Reported EPS Tops Expectations in Latest Trading; Post-Earnings: The Stock Gains 1.67% for the Current SessionBalance Sheet Strength - vinanet.vn
Rice Hall James & Associates LLC Purchases Shares of 93,396 Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira BioSciences Inc (PCRX) Chief Medical Officer Jonathan Slo - GuruFocus
Pacira BioSciences (NASDAQ:PCRX) Insider Jonathan Slonin Sells 3,040 Shares of Stock - MarketBeat
Pacira BioSciences (PCRX) CMO sells 3,040 shares in 10b5-1 plan - Stock Titan
Pacira (PCRX) Daily Price Brief: Records a 2.17% Increase to $23.75 in Latest Trading; Technical Focus: $22.56 and $24.94 Define the Nearby Reference Levels on the DayBPI Bull Correction - vinanet.vn
Pacira BioSciences (NASDAQ: PCRX) faces $70.6K share sale in 2026 - Stock Titan
Pacira BioSciences (NASDAQ:PCRX) Coverage Initiated at Truist Financial - MarketBeat
Truist Financial Upgrades Pacira BioSciences(PCRX.US) to Buy Rating, Raises Target Price to $30 - Moomoo
1.99%
2.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):